Floatz logo

Zofran

Recurrent Diffuse Large B-Cell Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma cohort.

View all 50

Same molecule, other indications

Zofran is also rated in:

NauseaDormant
BBB
Indicative ·
73 / 100
View asset →
VomitingDormant
BBB
Indicative ·
73 / 100
View asset →
Non-Hodgkin's LymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →